Ocular Therapeutix (OCUL) Equity Ratio (2013 - 2026)

Ocular Therapeutix's Equity Ratio history runs 14 years deep, the most recent figure standing at 0.79 for Q1 2026.

• In Q1 2026, Equity Ratio rose 21.19% year-over-year to 0.79; the TTM figure through Mar 2026 stood at 0.79 (up 21.19% YoY), while the FY2025 annual figure was 0.81, up 17.59% from the prior year.
• Equity Ratio was 0.79 for Q1 2026 at Ocular Therapeutix, down from 0.81 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.81 in Q4 2025 to a low of 0.03 in Q2 2023.
• Historically, Equity Ratio has averaged 0.49 across 5 years, with a median of 0.63 in 2025.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio plunged 93.38% in 2023, then jumped 2799.88% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.24 in 2022, then jumped by 52.56% to 0.36 in 2023, then surged by 90.47% to 0.69 in 2024, then gained by 17.59% to 0.81 in 2025, then retreated by 1.95% to 0.79 in 2026.
• The last three Equity Ratio figures came in at 0.79 (Q1 2026), 0.81 (Q4 2025), and 0.63 (Q3 2025), per Business Quant data.